A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2013
At a glance
- Drugs Cabotegravir (Primary) ; Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 26 Aug 2013 Results published in the Antimicrobial Agents and Chemotherapy.
- 01 Jun 2012 Actual number of patients changed from 44 to 56, as reported by ClinicalTrials.gov.
- 22 Mar 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History